Sat, Jan 31, 2015, 6:58 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

PDL BioPharma, Inc. Message Board

  • RSPC1 RSPC1 Feb 19, 2002 7:31 PM Flag

    PDLI response


    Here is the response from Jim Goff, Sr. Director of Corporate Communications at PDLI to my e-mail inquiry regarding company's position on the SG Cowen analyst's comments:

    "Thanks for your question in regard to PDL and the Cowen report. We continue to point out that it is premature to make judgments about Zenapax as a maintenance agent in psoriais. The Phase II study is still blinded. We do not yet know the results, nor can anyone know the results at this point in time. We expect to unblind the study and release the results via press release in the latter part of March.

    Thanks again for your interest in PDL."

    James Goff
    Sr. Director, Corporate Communications
    Protein Design Labs, Inc.

    I would like to note that PDL responded to my inquiry in a very timely manner. I have confidence that we will bounce back from this allegation.

    This topic is deleted.
7.29-0.14(-1.88%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
NASDAQFri, Jan 30, 2015 4:00 PM EST
Gran Tierra Energy, Inc.
AMEXFri, Jan 30, 2015 4:01 PM EST